ANI Pharmaceuticals, Inc.
NASDAQ:ANIPDrug Manufacturers - Specialty & Generic
-$1.42 today
- Market cap
- $1.62B
- Beta
- 0.44
- P/E (TTM)
- 18.5
- EPS (TTM)
- $4.29
Volume 0.29M
Average 0.35M
ANIP Other Non-current Assets
Long-term assets not reported separately.
ANI Pharmaceuticals, Inc.NASDAQ: ANIP
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 12.2% from a year ago
Other non-current assets stood at $11.58M at the end of Q1 FY2026, up 12.2% from a year earlier and down 15.5% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.
Context
- Other non-current assets amounted to 0.8% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +12.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 13.71M USD
- Year-over-year change
- +12.2%
- 4-year CAGR
- +57.9%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.71M | +12.2% |
| FY2024 | 2024-12-31 | 12.22M | +108.1% |
| FY2023 | 2023-12-31 | 5.87M | -48.3% |
| FY2022 | 2022-12-31 | 11.36M | +415.2% |
| FY2021 | 2021-12-31 | 2.21M | — |
Other Non-current Assets vs competitors
How ANIP compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +12.2% is the 5th highest of 9, against a peer median of +27.5%.
- Other non-current assets amounts to 0.8% of total assets for ANIP, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | ₹5.24B INR | +9.4% | +9.6% | 0.9% | |
| Jun 2026 | $801.1M USD | +3.8% | +8.7% | 2.3% | |
| Jun 2026 | $388M USD | -17.4% | -2.8% | 1.0% | |
| Jun 2026 | $358M USD | -7.7% | +5.0% | 1.4% | |
| Jun 2026 | $61.12M USD | +135.7% | +41.5% | 1.6% | |
| Mar 2026 | $33.48M USD | +45.6% | +14.3% | 2.0% | |
| Mar 2026 | $17.12M USD | +181.4% | +96.9% | 1.0% | |
| Mar 2026 | $11.58M USD | +12.2% | +6.5% | 0.8% | |
| Dec 2025 | $8.7M USD | — | — | 3.7% | |
| Mar 2026 | $1.65M USD | +83.1% | -24.7% | 0.7% | |
| Mar 2026 | $0 USD | — | -15.3% | 0.0% | |
| Peer median (excluding ANIP) | — | +27.5% | +8.7% | 1.2% | |
Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 100.3M | 48.23M | 221.12M | 144.86M | 285.59M |
| Short-term Investments | 0 | 0 | 0 | 6.31M | 0 |
| Net Receivables | 128.53M | 165.44M | 162.08M | 221.73M | 281.08M |
| Inventory | 81.69M | 105.36M | 111.2M | 136.78M | 143.07M |
| Other Current Assets | 3.67M | 21.41M | 25.42M | 18.01M | 43.38M |
| Total Current Assets | 321.78M | 344.26M | 519.82M | 527.68M | 753.12M |
| Property, Plant & Equipment (Net) | 52.67M | 43.25M | 44.59M | 56.86M | 62.48M |
| Goodwill | 27.89M | 28.22M | 28.22M | 59.99M | 62.48M |
| Intangible Assets | 294.12M | 251.64M | 209.01M | 541.83M | 479.53M |
| Long-term Investments | 5M | 0 | 6.2M | 0 | 0 |
| Tax Assets | 67.94M | 81.36M | 90.71M | 85.11M | 69.07M |
| Other Non-current Assets | 2.21M | 11.36M | 5.87M | 12.22M | 13.71M |
| Total Non-current Assets | 449.82M | 415.83M | 384.61M | 756.01M | 687.26M |
| Total Assets | 771.6M | 760.09M | 904.42M | 1.28B | 1.44B |
| Account Payables | 22.97M | 29.31M | 36.68M | 45.66M | 62.58M |
| Short-term Debt | 850K | 850K | 850K | 9.17M | 17.27M |
| Tax Payables | 3.67M | 0 | 8.16M | 6.75M | 11.03M |
| Deferred Revenue | 87K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 44.27M | 43.71M | 65.73M | 77.03M | 198.26M |
| Total Current Liabilities | 87.54M | 99.44M | 145.48M | 193.68M | 278.11M |
| Long-term Debt | 286.52M | 285.67M | 284.82M | 614.92M | 307.93M |
| Deferred Tax Liabilities | 9.49M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | (9.49M) | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 38.8M | 36.44M | 16.53M | 46.57M | 313.61M |
| Total Non-current Liabilities | 325.32M | 322.11M | 301.35M | 661.49M | 621.54M |
| Total Liabilities | 412.86M | 421.55M | 446.82M | 855.17M | 899.65M |
| Common Stock | 1K | 1K | 2K | 2K | 3K |
| Retained Earnings | (47.77M) | (97.29M) | (80.13M) | (100.28M) | (23.1M) |
| Accumulated OCI | (3.06M) | 12.17M | 8.86M | 5.34M | 1.03M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 358.74M | 338.54M | 457.6M | 428.53M | 540.72M |
| Total Debt | 287.37M | 286.52M | 285.67M | 624.09M | 325.2M |
| Net Debt | 187.07M | 238.29M | 64.55M | 479.23M | 39.61M |
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
Intrinsic Alpha fair value
Locked
Current Price
$71.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.